Zymeworks Inc
NASDAQ:ZYME

Watchlist Manager
Zymeworks Inc Logo
Zymeworks Inc
NASDAQ:ZYME
Watchlist
Price: 14.29 USD 4.46% Market Closed
Market Cap: 988.3m USD
Have any thoughts about
Zymeworks Inc?
Write Note

Intrinsic Value

ZYME's intrinsic value estimate is unreliable because it is based only on its multiples and doesn't use a DCF valuation.

The intrinsic value of one ZYME stock under the Base Case scenario is 18.38 USD. Compared to the current market price of 14.29 USD, Zymeworks Inc is Undervalued by 22%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

ZYME Intrinsic Value
18.38 USD
Undervaluation 22%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation Backtest
Zymeworks Inc

Backtest Intrinsic Value
Dive into the past to invest in the future

Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.

Start backtest now and learn if your stock is truly undervalued or overvalued!

Run Backtest
Backtest Conclusion
Very Attractive
Current Valuation
+45%
Avg Valuation
-12%
Worst Valuation
-49%
Best Valuation
+45%

Stock is trading at its lowest valuation over the past 5 years.

Backtest Example
Register to View Results
Register to View Results

To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.

Backtest Unavailable

The backtest for ZYME cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.

Backtest In Progress...
Backtest In Progress...
How do you feel about ZYME?
Bearish
Neutral
Bullish

Fundamental Analysis

Economic Moat
Zymeworks Inc

Company Quality
No Indicators Selected
Select Indicators

Select up to 3 indicators:

Insider Trading
0-3
Months
0-6
Months
0-12
Months
0-36
Months
No Periods Selected
Select Periods

Select up to 2 periods:

Investment Journal
AI Assistant
AI Assistant
Ask me anything about Zymeworks Inc

Provide an overview of the primary business activities
of Zymeworks Inc.

What unique competitive advantages
does Zymeworks Inc hold over its rivals?

What risks and challenges
does Zymeworks Inc face in the near future?

Has there been any significant insider trading activity
in Zymeworks Inc recently?

Summarize the latest earnings call
of Zymeworks Inc.

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Zymeworks Inc.

Provide P/S
for Zymeworks Inc.

Provide P/E
for Zymeworks Inc.

Provide P/OCF
for Zymeworks Inc.

Provide P/FCFE
for Zymeworks Inc.

Provide P/B
for Zymeworks Inc.

Provide EV/S
for Zymeworks Inc.

Provide EV/GP
for Zymeworks Inc.

Provide EV/EBITDA
for Zymeworks Inc.

Provide EV/EBIT
for Zymeworks Inc.

Provide EV/OCF
for Zymeworks Inc.

Provide EV/FCFF
for Zymeworks Inc.

Provide EV/IC
for Zymeworks Inc.

Show me price targets
for Zymeworks Inc made by professional analysts.

What are the Revenue projections
for Zymeworks Inc?

How accurate were the past Revenue estimates
for Zymeworks Inc?

What are the Net Income projections
for Zymeworks Inc?

How accurate were the past Net Income estimates
for Zymeworks Inc?

What are the EPS projections
for Zymeworks Inc?

How accurate were the past EPS estimates
for Zymeworks Inc?

What are the EBIT projections
for Zymeworks Inc?

How accurate were the past EBIT estimates
for Zymeworks Inc?

Compare the revenue forecasts
for Zymeworks Inc with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Zymeworks Inc and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Zymeworks Inc against its competitors.

Analyze the profit margins
(gross, operating, and net) of Zymeworks Inc compared to its peers.

Compare the P/E ratios
of Zymeworks Inc against its peers.

Discuss the investment returns and shareholder value creation
comparing Zymeworks Inc with its peers.

Analyze the financial leverage
of Zymeworks Inc compared to its main competitors.

Show all profitability ratios
for Zymeworks Inc.

Provide ROE
for Zymeworks Inc.

Provide ROA
for Zymeworks Inc.

Provide ROIC
for Zymeworks Inc.

Provide ROCE
for Zymeworks Inc.

Provide Gross Margin
for Zymeworks Inc.

Provide Operating Margin
for Zymeworks Inc.

Provide Net Margin
for Zymeworks Inc.

Provide FCF Margin
for Zymeworks Inc.

Show all solvency ratios
for Zymeworks Inc.

Provide D/E Ratio
for Zymeworks Inc.

Provide D/A Ratio
for Zymeworks Inc.

Provide Interest Coverage Ratio
for Zymeworks Inc.

Provide Altman Z-Score Ratio
for Zymeworks Inc.

Provide Quick Ratio
for Zymeworks Inc.

Provide Current Ratio
for Zymeworks Inc.

Provide Cash Ratio
for Zymeworks Inc.

What is the historical Revenue growth
over the last 5 years for Zymeworks Inc?

What is the historical Net Income growth
over the last 5 years for Zymeworks Inc?

What is the current Free Cash Flow
of Zymeworks Inc?

Discuss the annual earnings per share (EPS)
trend over the past five years for Zymeworks Inc.

Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
Zymeworks Inc

Current Assets 343.8m
Cash & Short-Term Investments 297.2m
Receivables 23.7m
Other Current Assets 22.9m
Non-Current Assets 143.4m
Long-Term Investments 77.7m
PP&E 35.7m
Intangibles 18.6m
Other Non-Current Assets 11.4m
Current Liabilities 83.9m
Accounts Payable 3.4m
Accrued Liabilities 50.4m
Other Current Liabilities 30.1m
Non-Current Liabilities 36.3m
Long-Term Debt 33k
Other Non-Current Liabilities 36.2m
Efficiency

Earnings Waterfall
Zymeworks Inc

Revenue
62.2m USD
Operating Expenses
-183.2m USD
Operating Income
-121m USD
Other Expenses
7.4m USD
Net Income
-113.7m USD

Free Cash Flow Analysis
Zymeworks Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate
Fundamental Scores

ZYME Profitability Score
Profitability Due Diligence

Zymeworks Inc's profitability score is 27/100. The higher the profitability score, the more profitable the company is.

Exceptional 3-Years Revenue Growth
ROE is Increasing
ROIC is Increasing
Exceptional Revenue Growth Forecast
27/100
Profitability
Score

Zymeworks Inc's profitability score is 27/100. The higher the profitability score, the more profitable the company is.

ZYME Solvency Score
Solvency Due Diligence

Zymeworks Inc's solvency score is 73/100. The higher the solvency score, the more solvent the company is.

Short-Term Solvency
Long-Term Solvency
Negative Net Debt
Low D/E
73/100
Solvency
Score

Zymeworks Inc's solvency score is 73/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

ZYME Price Targets Summary
Zymeworks Inc

Wall Street analysts forecast ZYME stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for ZYME is 17.79 USD with a low forecast of 12.12 USD and a high forecast of 29.4 USD.

Lowest
Price Target
12.12 USD
15% Downside
Average
Price Target
17.79 USD
24% Upside
Highest
Price Target
29.4 USD
106% Upside
View Analyst Estimates
View Analyst Estimates
Want to learn more about Wall St estimates for ZYME?

Click here to dive deeper.

Dividends

Zymeworks Inc
does not pay dividends
Shareholder Yield

Current shareholder yield for ZYME is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
No dividends
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Ownership

ZYME Insider Trading
Buy and sell transactions by insiders

Cumulative Transactions Amount
Period Sold Bought Net
3 Months
6 Months
9 Months
12 Months
Why is insider trading important?

Profile

Zymeworks Inc Logo
Zymeworks Inc

Country

United States of America

Industry

Biotechnology

Market Cap

1B USD

Dividend Yield

0%

Description

Zymeworks Inc. is a biopharmaceutical company. The company is headquartered in Middletown, Delaware and currently employs 286 full-time employees. The company went IPO on 2019-06-24. Its lead product candidate is zanidatamab, a bispecific antibody that targets two distinct domains of the human epidermal growth factor receptor 2 (HER2). Its product candidate ZW49, combines the design of zanidatamab with its ZymeLink ADC platform, comprised of its cytotoxin and cleavable linker. The firm operates through a number of platforms, including Azymetric, ZymeLink, EFECT and ProTECT. Its Azymetric is a bispecific platform that enables therapeutic antibodies to simultaneously bind multiple distinct locations on a target or to multiple targets. The Company’s ZymeLink is an antibody-drug conjugate (ADC) platform comprised of cytotoxins and the linker technology used to couple these cytotoxins to tumor-targeting antibodies or proteins.

Contact

DELAWARE
Middletown
108 Patriot Drive, Suite A
+13022748744
www.zymeworks.com

IPO

2019-06-24

Employees

286

Officers

Senior VP, Corporate Secretary & General Counsel
Mr. Daniel Dex J.D., Ph.D.
Senior Manager of Corporate Communications
Diana Papove
Vice President of Corporate Development
Dr. Lindsey Foulkes B.Sc., Ph.D.
Vice President of Human Resources & DEI
Ms. Laura O'Connor
Senior Vice President of Process Sciences
Mr. John Fann Ph.D.
Senior Director of Corporate Affairs
Dr. Ryan Dercho Ph.D.
Show More
Director of Multispecific Antibody Therapeutics
Nina Weisser Ph.D.
Director of Protein Engineering
Thomas Spreter Von Kreudenstein Ph.D.
Show Less

See Also

Discover More
What is the Intrinsic Value of one ZYME stock?

The intrinsic value of one ZYME stock under the Base Case scenario is 18.38 USD.

Is ZYME stock undervalued or overvalued?

Compared to the current market price of 14.29 USD, Zymeworks Inc is Undervalued by 22%.

Back to Top